A phase I-II study of docetaxel and atrasentan in men with castration-resistant metastatic prostate cancer.
about
Recent progress in pharmaceutical therapies for castration-resistant prostate cancerDocetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trialClinical pharmacology of an atrasentan and docetaxel regimen in men with hormone-refractory prostate cancer2017 update on the relationship between diabetes and colorectal cancer: epidemiology, potential molecular mechanisms and therapeutic implicationsNovel targeted therapeutics for metastatic castration-resistant prostate cancer.Recent advances in bone-targeted therapies of metastatic prostate cancerEfficacy and safety of docetaxel plus prednisolone chemotherapy for metastatic hormone-refractory prostate adenocarcinoma: single institutional study in Korea.Phase Ib Study of Enzalutamide in Combination with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer.Anti-endothelin drugs in solid tumors.Evolving role of bone biomarkers in castration-resistant prostate cancer.Preliminary study of the specific endothelin a receptor antagonist zibotentan in combination with docetaxel in patients with metastatic castration-resistant prostate cancer.Emerging therapies in metastatic bone pain.Targeting the endothelin receptor in prostate cancer bone metastasis: Back to the mouse?Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancerRole of the endothelin axis and its antagonists in the treatment of cancerOnce-daily dasatinib: expansion of phase II study evaluating safety and efficacy of dasatinib in patients with metastatic castration-resistant prostate cancer.Potential use of custirsen to treat prostate cancer.Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from a phase 1-2 study.Therapeutic potential of endothelin receptor modulators: lessons from human clinical trials.Docetaxel-based combination therapy for castration-resistant prostate cancer.Research in castration-resistant prostate cancer: what does the future hold?Endothelins and their receptors in cancer: identification of therapeutic targets.Castration-resistant prostate cancer: targeted therapies.Current clinical trials in castrate-resistant prostate cancer.New strategies for medical management of castration-resistant prostate cancer.The changing therapeutic landscape of castration-resistant prostate cancer.Castration-resistant prostate cancer: many treatments, many options, many challenges ahead.Current and emerging treatment options for castration-resistant prostate cancer: a focus on immunotherapyNovel options for the treatment of castration-resistant prostate cancer.Targeting the endothelin axis in prostate carcinoma.Docetaxel: a review of its use for the first-line treatment of advanced castration-resistant prostate cancer.Antimitotic agents for the treatment of patients with metastatic castrate-resistant prostate cancer.Regulation of androgen receptor expression through angiotensin II type 1 receptor in prostate cancer cells.Atrasentan (ABT-627) enhances perfusion and reduces hypoxia in a human tumor xenograft model.Phase III trials with docetaxel-based combinations for metastatic castration-resistant prostate cancer: time to learn from past experiences.Phase III, randomized, placebo-controlled study of once-daily oral zibotentan (ZD4054) in patients with non-metastatic castration-resistant prostate cancer.Optimal management of bone metastases in prostate cancer.
P2860
Q27022567-98129AFC-6E35-45B3-90AD-13DDD891D10EQ28294857-4D25FF94-A85F-44AE-BC0B-E263D0AFE565Q29006772-779B47C9-8416-488D-A88F-F3835EBFC940Q30239808-42CC672D-843A-49DC-8955-B904892BFE1FQ33642278-7CF1E8FE-591E-40A6-8B74-022773EB36C3Q33703763-988DD3EE-85EA-42C9-8B15-6A11F4FC1256Q33766472-4874952F-BBDF-415F-844D-A3B18FDAED5FQ33789192-A6955BF3-73CC-4AD6-9EE7-6262B780E3CCQ34021011-283B8E32-6AB8-4FDF-9B7A-09BB37DB7388Q34023877-E654A541-FF5A-412C-8689-00683F5A431DQ34161050-CBDD0E82-A483-4A6A-A96A-6D6F228DD533Q34182919-C1C0FD5B-F24F-4A55-9165-E8FFF72EBE09Q34509741-7CFB2B8D-C065-4896-A1EF-ACF98D0C9E0FQ34613941-F50A6086-64B1-4BBC-9302-06C55E78CA71Q34919570-E9777ACE-C2E6-4D1C-B406-5AE620B1FF9AQ36087899-8CF0D744-F91C-43F7-868A-24E8212791EDQ36975969-0173AF74-3E82-4135-9E13-D9883C7A5F80Q37502039-E4F6E334-47C2-43C5-8AF3-6BCFE0B65FFCQ37573815-B8EEE6F7-D695-4A24-AA99-53BA12AEB40BQ37721016-D61F7A79-CA54-41EE-89EA-B84A4260F658Q37794802-2EF853C5-4729-4C1D-A675-E8556FCAA87CQ37830914-B7D4B55C-EAFC-47D1-85B4-500AAE93CBB6Q37856646-9002402E-FC8C-40BE-A413-0A5C9DA91212Q37870805-0B54446F-82EA-42F9-B529-09DC212238AAQ37876123-0C40655D-AC6C-47C8-B1A7-0209BCC1BED8Q37913983-02FC06B8-584E-4DB5-8A4D-62EBCA3F6BCBQ37950948-6603AEB1-8872-49BC-BB39-B8483A8C5CA0Q37952147-31268880-3DF6-47D3-B7EC-2288924328B5Q37958741-E4199139-A18F-4217-A7BA-D6384925A379Q37971873-BD4CE738-C020-4C90-8F4A-A08F656EB752Q38028012-FB5C6EBB-F695-40B7-89A9-EF0C3EF88474Q38099046-0601A100-30A2-4C5D-B041-194DBA719BE1Q39548383-7DAE0D24-CFF2-46A1-B5DF-E16EADDD42C7Q41484298-FCE2E321-7397-491B-A696-3EE5AC624914Q42927772-1AA0FF87-2975-4398-A3E1-DE0285E49AB8Q45883136-08CE52AD-041D-48B7-B8C9-E321FBAFFF6EQ53266501-BBA29706-B884-47E7-980C-F996BE326793
P2860
A phase I-II study of docetaxel and atrasentan in men with castration-resistant metastatic prostate cancer.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
A phase I-II study of docetaxe ...... nt metastatic prostate cancer.
@en
A phase I-II study of docetaxe ...... nt metastatic prostate cancer.
@nl
type
label
A phase I-II study of docetaxe ...... nt metastatic prostate cancer.
@en
A phase I-II study of docetaxe ...... nt metastatic prostate cancer.
@nl
prefLabel
A phase I-II study of docetaxe ...... nt metastatic prostate cancer.
@en
A phase I-II study of docetaxe ...... nt metastatic prostate cancer.
@nl
P2093
P1476
A phase I-II study of docetaxe ...... nt metastatic prostate cancer.
@en
P2093
Andrew J Armstrong
Cassandra Moore
Daniel J George
Darryl Sleep
Herbert Hurwitz
James Turnbull
Jon P Gockerman
Patricia Creel
Sarah Yenser
Sherri Haley
P304
P356
10.1158/1078-0432.CCR-08-1085
P407
P577
2008-10-01T00:00:00Z